At the time of diagnosis of T2D in a patient with clinical ASCVD
Also approved under the CNPV pilot, Foundayo is a once-daily, oral nonpeptide GLP-1 that requires dose titration to mitigate gastrointestinal side effects
However, unlike FDA-approved medications, compounded versions are not reviewed by the FDA for safety, effectiveness, or quality
The Bigger Picture: HSAs and Expanded Eligibility Support GLP-1 Affordability Many employees paying for GLP-1s rely on HSAs to cover these drugs tax-free to lower out-of-pocket costs
In consideration of the multiple metabolic and cardiovascular effects seen in subjects treated with GLP-1RAs and SGLT-2is (e.g., reduction of hyperglycemia, weight loss, free/fat mass and bone remodeling, anti-atherosclerosis, natriuresis), it is reasonable to speculate that GH and IGF-1 may play a about a relevant role in this context